Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPK/PD of piperacillin tazobactam in infections with or without liver cirrhosis
ChiCTR2400086031Phase 4Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Jun 2024
- Modality
- Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of piperacillin + tazobactam in bacterial disease (2 arms), sponsored by Nanjing Drum-Tower Hospital. Primary endpoint: Clinical efficacy at Day 7. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
piperacillin + tazobactam
03
Conditions
bacterial disease
Beyond the preview
Go deeper on ChiCTR2400086031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086031.